Dr. Sayoni Bhanja

MRCP (UK) Medical Oncology (2025)
DrNB Medical Oncology, Apollo Multispecialty Hospitals Limited, Kolkata, National Board of Examinations in Medical Sciences (2020 - 2023)
DNB Radiation Oncology, Chittaranjan National Cancer Institute (CNCI), Kolkata, National Board of Examinations (2016 – 2018)
DMRT, IPGME&R and SSKM Hospital (P.G. Hospital), Kolkata (2013 - 2015)
MBBS, Bankura Sammilani Medical College and Hospital (BSMCH), Calcutta University (2002 – 2007)

Consultant Medical Oncologist, Karkinos Medella Oncology lnstitute (November 2024 - Present)
Consultant Medical Oncologist, Ruby General Hospital and Cancer Centre (March 2024 December 2024)
DrNB Medical Oncology Post-Doctoral Trainee, Apollo Multispecialty Hospitals Limited (Academic Sr.) (December 2020 – December 2023)
Consultant Medical Oncologist, B. P. Poddar Hospital & Medical Research Limited (November 2019 – December 2020)
Sr. Resident in Department of Medical Oncology, Chittaranjan National Cancer Institute (CNCI), Kolkata (June 2018 – October 2019)
DNB Radiation Oncology (Academic Jr.), Chittaranjan National Cancer Institute (CNCI), Kolkata (March 2016 – March 2018)
DMRT (Academic Jr.), IPGME&R and SSKM Hospital (P.G. Hospital), Kolkata (July 2013 - July 2015)

ADDITIONAL TRAININGS

Preceptorship in Breast Cancer, Memorial Sloan Kettering Cancer Center (MSKCC), USA.
Preceptorship in Immuno-Oncology, Harvard Medical School, USA.

Experienced with diagnosis and treatment of solid and haematological cancers.
Experience of participating in multidisciplinary tumor board.
Exposure to all types of modern investigations, radiological interventions.
Exposure to theragnostic with advances in nuclear medicine.
Exposure to modern surgical procedures including robotic surgery and HIPEC.
Exposure to modern Radiotherapy including SRT, SBRT.
Hands on training with modern medicine (targeted agents, Immune checkpoint inhibitors, chemotherapy).
Hands on training in BMT.
Hands on training in critical care in ICU, HDU.
Conducting clinical research.
Conducting and managing day care patients with chemotherapy, IO administration with various types of central lines including PICC, Chemo port in tertiary cancer center.
IPD patient rounds with individualized treatment decision

ASCO-Abstract#276367: Tumor-associated myeloid-derived suppressor cells as a potential biomarker for prognostication of response in treatment of diffuse large cell lymphoma.
Bhanja, S., Lahiri, D., Roy, S., Maji, T., & De, P. (2023). Comparison of Safety and Efficacy of Two Different Chemotherapy Dosing Schedules used in Concurrent Chemoradiation of Head and Neck Cancer: A Retrospective Experience from a Tertiary Cancer Care Institute of Eastern India.
Asia Pacific Journal of Cancer Care, 8(3), Pages 477-482
https://coi.asco.org/Report/ViewAbstractCOI?id=276367 Goyel, D., Maji, T., Lahiri, D., Roy, S., Bhanja, S., Rangineni, S., Kumar Ray, D., Kumar Mahanta, B., Kumar Misra, D., De, P. (2023). Hippocampal avoidance whole brain radiotherapy in brain metastasis using volumetric modulated arc therapy: experience from a Regional Cancer Centre of Eastern India
Reports of Practical Oncology and Radiotherapy 2023, Volume 28, Number 4, Pages 468-477 (DOI: 10.5603/RPOR.a2023.0048)

Consultant Medical Oncologist